MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2019 International Congress

    Continuous circadian intracerebroventricular administration of anaerobic dopamine: A new therapeutic concept for Parkinson’s disease?

    C. Moreau, C. Laloux, C. Lachaud, E. Pioli, Q. Li, P. Pascal, L. Defebvre, R. Bordet, E. Bezard, M. Fisichella, D. Devos (Lille, France)

    Objective: We aim to overcome these challenges by demonstrating that continuous i.c.v. of Anaerobic-dopamine (A-dopamine,Patent #WO2015173258 A1) close to the striatum is a feasible and…
  • 2019 International Congress

    GABA-A Receptor Positive Allosteric Modulators: Phase 2 Proof of Concept Studies of Brexanolone Injection and SAGE-217 in Essential Tremor

    J. Paskavitz, A. Bullock, D. Nguyen, A. Smith, B. Farley, M. Quirk, I. Kaul, S. Li, A. Ellenbogen, C. Silber, J. Doherty, H. Colquhoun, S. Kanes (Cambridge, MA, USA)

    Objective: To examine use of γ-aminobutyric acid (GABA) type A receptor (GABA-A-R) positive allosteric modulators (PAMs) in the treatment of essential tremor (ET) in early…
  • 2019 International Congress

    Addition of Opicapone to Safinamide in Parkinson’s Disease patients

    M. Russo, C. Carrarini, F. Dono, M. Di Pietro, M. Rispoli, L. Ferri, M. Onofrj (Chieti, Italy)

    Objective: To assess safety and efficacy of Opicapone in patients treated with Levodopa and Safinamide presenting early morning “off” states and akinesia. Background: Safinamide is…
  • 2019 International Congress

    Impact of ND0612 on patient reported outcomes: A blinded rater study of 2 dosing regimens

    F. Stocchi, W. Poewe, S. Oren, R. Case, K. Kieburtz, C. Olanow (Rome, Italy)

    Objective: Primary analyses of this Phase 2 study have demonstrated significant efficacy of ND0612 in reducing OFF time and improving motor status. This secondary analysis…
  • 2019 International Congress

    SAFINAMIDE IN DAILY CLINICAL PRACTICE: ASSESSMENT OF EFFICACY AND TOLERABILITY IN PARKINSON´S DISEASE

    A. Vinagre-Aragón, E. Mondragón-Rezola, I. Croitoru, A. Bergareche-Yarza, JJ. Poza-Aldea, A. Olaskoaga-Caballer, M. Iridoy-Zulet, M. Ruibal-Salgado, JC. Gómez-Esteban, K. Berganzo-Corrales, B. Tijero-Merino, J. Ruiz-Martínez (San Sebastián, Spain)

    Objective: to analyze the long term efficacy and tolerability of safinamide added as adjunctive therapy in a series of patients with Parkinson´s disease (PD) Background:…
  • 2019 International Congress

    Two novel ANO10 mutations causing adult-onset autosomal recessive spinocerebellar ataxia

    B. Bergmans, S. Donatello, M. Pandolfo, C. Depondt (Brugge, Belgium)

    Objective: Clinical and genetic characterization of a patient Background: In recent years mutations more than 100 different genes have been shown to underlie spinocerebellar ataxias.…
  • 2019 International Congress

    Opsoclonus-myoclonus-ataxia syndrome associated to rubella

    BED. Ines, BRA. Zeineb, HAM. Salma, ZAO. Jamel, MRI. Ridha (Tunis, Tunisia)

    Objective: Reporting exceptional etiology of OMS and  remembering  spectrum of neurological manifestations of rubella. Background: Opsoclonus-myoclonus-ataxia (OMS) is a rare child clinical paraneoplastic syndrome. OMS…
  • 2019 International Congress

    Respiratory Function and Functional Decline in Spinocerebellar Ataxia Type 2

    N. Mello, M. Zonta, H. Teive, A. Meira, B. Zeigelboim (Curitiba, Brazil)

    Objective: To evaluate the relationship between the values of Peak Expiratory Flow rate (PEFr), Maximum Inspiratory Pressure (MIP), the presence of respiratory complaints with disease…
  • 2019 International Congress

    Alignment of objective markers of speech with listener based judgements and disease severity in Friedreich ataxia

    A. Vogel, A. Tsanas, H. Reece, L. Corben, G. Tai, M. Delatycki (Melbourne, Australia)

    Objective: To identify a subset of acoustic markers of speech that objectively describe listener perceptions, disease severity and speech related quality of life in Friedreich…
  • 2019 International Congress

    Post-pump chorea and progressive supranuclear palsy like syndrome following major cardiac surgery: A case series

    GW. Kim, KW. Park, NR. Choi, HS. Ryu, HJ. Kim, CS. Lee, SJ. Chung (Daegu, Republic of Korea)

    Objective: We report three patients who developed movement disorders after major cardiac surgery and suggest a common underlying mechanism. Background: Choreiform movement disorder occurs in…
  • « Previous Page
  • 1
  • …
  • 14
  • 15
  • 16
  • 17
  • 18
  • …
  • 217
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley